Acute leukemia

Acute lymphatic leukemia, acute or chronic myelogenous leukemia... [Pg.586]

Acute leukemia, acute lymphoma, short-bowel syndrome, liver disease (decreased clearance), diabetes mellitus, mitochondrial disease, and congenital enzyme deficiencies... [Pg.177]

Cancers Multiple myeloma Non-Hodgkin s lymphoma Hodgkin s disease Acute myeloid leukemia Neuroblastoma Germ cell tumors Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myeloid leukemia Myelodysplastic syndrome Myeloproliferative disorders Non-Hodgkin s lymphoma Hodgkin s disease Chronic lymphocytic leukemia Multiple myeloma... [Pg.1448]

ALL Acute lymphoblastic leukemia acute lymphocytic BID Twice daily (bis in die)... [Pg.1553]

Acute lymphoblastic leukemia acute and chronic myelogenous leukemias Acute lymphoblastic leukemia Burkitt s lymphoma trophoblastic choriocarcinoma ... [Pg.654]

Ovarian adenocarcinoma, Breast carcinoma, Hodyhin s disease, non-Hodgkin s lymphoma, multiple myeloma, leukemia (acute lymphoblastic, acute myelogenous, acute monocytic, chronic granulocytic, chronic lymphocytic), mycosis fungoides, disseminated neuroblastoma, retinoblastoma PO 1-5 mg/kg/day. IV 40-50 mg/kg in divided doses over 2-5 days or 10-15 mg/kg every 7-10 days or 3-5 mg/kg twice a week. Biopsy-proven minimal-change nephrotic syndrome PO 2 5-3 mg/kg/day for 60-90 days. [Pg.314]

In June 1999, phase I clinical trials of OTI-010 were initiated in cancer patients receivingchemotherapy and HSC transplantation for the treatment of high-risk hematological malignancies (including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and non-Hodgkin s lymphoma). The multicenter studies, conducted in seven US and European cancer centers, showed OTI-010 to be safe and efficacious, with 52% of patients ( 40 patients) responding positively to the therapy [327297], [495015]. [Pg.65]

Cyclophosphamide Cytoxan, Neosar Acute and chronic lymphocytic leukemia acute and chronic myelocytic leukemia carcinoma of ovary, breast Hodgkin disease non-Hodgkin lymphomas multiple myeloma Blood disorders (anemia, leukopenia, thrombocytopenia] Gl distress (nausea, vomiting, loss of appetite] bladder irritation hair loss car-diotoxicity pulmonary toxicity... [Pg.570]

Thioguanine Generic Acute lymphocytic leukemia acute and chronic myelocytic leukemia Blood disorders (anemia, leukopenia, thrombocytopenia] Gl distress (nausea, vomiting] hepatotoxicity... [Pg.572]

Hand, foot, and mouth disease Herpes zoster, disseminated Leukemia - acute Measles... [Pg.212]

Acute myeloid leukemia, minimally differentiated Acute myeloid leukemia without maturation Acute myeloid leukemia with maturation Acute myelomonocytic leukemia Acute monoblastic/acute monocytic leukemia... [Pg.2488]

Acute megakaryocytic leukemia Acute basophilic leukemia Acute panmyelosis with myelofibrosis Myeloid sarcoma... [Pg.2488]

Tyrosine kinase abl Translocation Cytoplasm Chronic myeloid leukemia Acute lymphoblastic leukemia... [Pg.322]

Lymphosarcoma, severe psoriasis, cancer of the head, neck, breast, lung, rheumatoid arthritis (RA) Alpha-interferon-refractory hairy cell leukemia Acute leukemias... [Pg.586]

Hormones has the ability to suppress mitosis in lymphocytes and this effect is duly utilized in the treatment of neoplastic diseases. Adrenocorticosteroids specifically are effective in the treatment of leukemia in children and in the management of hemolytic anaemia and hemorrhagic complications of thrombocytopenia that mostly occur in malignant lymphomas and chronic lymphocitic leukemia. Acute lymphoblastic leukemias in children are better treated with corticosteroids rather than antimetabolities and remission take place more rapidly. The hormones have been beneficial in breast cancer and other carcinomas although palliative effects are of short duration. [Pg.830]

Adrenocortico -steroids Inhibit DMA and protein synthesis as well as mitosis. Used for acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, multiple myeloma, breast cancer, and lymphoma. [Pg.131]

Inteimediate-and high-grade NHL Waldenstrom s macroglobulinemia Chronic lymphocytic leukemia Acute prolymphocytic leukemia Acute lymphoblastic leukemia Hodgkin s disease Cutaneous B-cell lymphoma Colon cancer and other solid tumors... [Pg.227]

Myxoid liposarcoma Myxoid liposarcoma Acute myeloid leukemia Acute myeloid leukemia Ewing s sarcoma Ewing s sarcoma Ewing s sarcoma Clear cell sarcoma... [Pg.124]

M5a acute monoblastic leukemia M5b acute monocytic leukemia, acute erythroblastic leukemia, acute megakaryoblastic leukemia. [Pg.177]

Other 2 -fluoro derivatives have been claimed in different patents [63,79] (Scheme 16). Generally, the cytotoxicity of the carminomycin, (4-hydroxy-IDA), and that of the 2 -fluoro derivative against a number of tumor cell lines are equal in vitro. Both compounds show the same activity in vivo in tests against murine P-388 leukemia. Acute toxicity of the fluorine compounds appears to be lower than carminomycin. Carminomycin is another natural glycoside within the family of the anthracyclines. [Pg.237]

Negative acute-phase reactant Sepsis, shock Disseminated intravascular coagulation Acute leukemia Acute pancreatitis Inherited deficit... [Pg.5287]

Leukemia, acute U Advanced disease all amino acids T H... [Pg.24]

There are two main types of leukemia acute leukemia and chronic leukemia. The acute leukemia is divided into two categories, depending upon their cell of origin. [Pg.617]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...